

LIST OF FIGURES

Figure No.	Figure	Page No.
Figure 2.1	Antioxidant phytochemicals and their mechanism of action to prevent different diseases	33
Figure 2.2	Relation between life style, oxidative stress, insulin resistance, inflammation and atherosclerosis.	34
Figure 2.3	The general mechanism of oxidative stress induced by various factors on liver diseases	35
Figure 2.4	Opportunity of drug discovery from Indian Traditional Herbal medicine	36
Figure 3	Study area for the documentation of traditional herbal knowledge from the herbal practitioners of West Sikkim and collection of medicinal plants	61
Figure 4.1.1.a	Areas under survey	64
Figure 4.1.1.b	Areas under survey (A: Malbasey; B: Darap) and the herbal practitioners who were interviewed for traditional knowledge of herbal medicines	65
Figure 4.1.1.c	The herbal practitioners who were interviewed for traditional knowledge of herbal medicines	67
Figure 4.1.1.d	Herbal practitioners (A: Lt. Phiprani Subba; B: Lt. Lakpa Lepcha); C and D: Conservation of medicinal plants in nursery; E: Herbal formulations stored in powder form; F: Traditional wooden grinder used to crush / grind medicinal plants for preparation of herbal formulations	67
Figure 4.1.2	Information of the traditional herbal practitioners about their age, gender and educational qualifications	68
Figure 4.1.3	Occupational status of the herbal practitioners	68
Figure 4.1.4	Medicinal plants collected from the survey area which were used to prepare the herbal formulations	69-71
Figure 4.1.5	Digital herbarium with authenticated accession numbers of medicinal plants collected during survey submitted at the Taxonomy & Environmental Biology Laboratory, Department of Botany, University of North Bengal	72-75

Figure No.	Figure	Page No.
Figure 4.1.6	List of the families of all the medicinal plants collected during survey used for the preparation of herbal formulations	76
Figure 4.1.7	Plant parts used for the preparation of herbal formulations	77
Figure 4.1.8	Mode of administration of the herbal formulations	77
Figure 4.2.1	Herbal formulations in dry powder form for organoleptic study	91
Figure 4.2.2.a	Observation in powder microscopy of a herbal formulation used for the treatment of heart palpitation which is abbreviated as HP	93
Figure 4.2.2.b	Observation in powder microscopy of a herbal formulation used for the treatment of arthritis which is abbreviated as AR	94
Figure 4.2.2.c	Observation in powder microscopy of a herbal formulation used for the treatment of asthma which is abbreviated as AS.	95
Figure 4.2.2.d	Observation in powder microscopy of a herbal formulation used for the treatment of gastritis which is abbreviated as GS	96
Figure 4.2.2.e	Observation in powder microscopy of a herbal formulation used for the treatment of high blood pressure which is abbreviated as BP.	97
Figure 4.2.2.f	Observation in powder microscopy of a herbal formulation used for the treatment of tonsilitis which is abbreviated as TS	98
Figure 4.2.2.g	Observation in powder microscopy of a herbal formulation used for the treatment of food poisoning which is abbreviated as FP	99
Figure 4.2.2.h	Observation in powder microscopy of <i>Fraxinus floribunda</i> bark used for the treatment of diabetes which is abbreviated as FF	100
Figure 4.2.2.i	Observation in powder microscopy of <i>Achyranthes aspera</i> root used for the treatment of throat infection which is abbreviated as AA	101

Figure No.	Figure	Page No.
Figure 4.2.2.j	Observation in powder microscopy of <i>Clematis buchanania</i> root used for the treatment of sinusitis which is abbreviated as CB	102
Figure 4.2.2.k	Observation in powder microscopy of <i>Hedyotis scandens</i> root used for the treatment of indigestion and stomachache which is abbreviated as HS	103
Figure 4.2.5.a	Thin layer chromatography of herbal formulations for the detection of anthraglycosides with Rf values	151
Figure 4.2.5.b	Thin layer chromatography of herbal formulations for the detection of arbutin with Rf values	152
Figure 4.2.5.c	Thin layer chromatography of herbal formulations for the detection of bitter principles with Rf values.	153
Figure 4.2.5.d	Thin layer chromatography of herbal formulations for the detection of flavonoids	154
Figure 4.2.5.e	Thin layer chromatography of herbal formulations for the detection of cardiac glycosides with Rf values	155
Figure 4.2.5.f	Thin layer chromatography of herbal formulations for the detection of alkaloids.	156
Figure 4.2.5.g	Thin layer chromatography of herbal formulations for the detection of coumarins with Rf values	157
Figure 4.3.1.a	Qualitative estimation of phytochemicals of herbal formulation used for the treatment of heart palpitation (HP)	160
Figure 4.3.1.b	Qualitative estimation of phytochemicals of herbal formulation used for the treatment of arthritis (AR)	160
Figure 4.3.1.c	Qualitative estimation of phytochemicals of herbal formulation used for the treatment of high blood pressure (BP)	161
Figure 4.3.1.d	Qualitative estimation of phytochemicals of herbal formulation used for the treatment of asthma (AS)	161

Figure No.	Figure	Page No.
Figure 4.3.1.e	Qualitative estimation of phytochemicals of herbal formulation used for the treatment of tonsillitis (TS)	162
Figure 4.3.1.f	Qualitative estimation of phytochemicals of herbal formulation used for the treatment of gastritis (GS)	162
Figure 4.3.1.g	Qualitative estimation of phytochemicals of <i>Achyranthes aspera</i> root used for the treatment of throat infection (AA)	163
Figure 4.3.1.h	Qualitative estimation of phytochemicals of <i>Clematis buchananiana</i> root used for the treatment of sinusitis (CB)	163
Figure 4.3.1.i	Qualitative estimation of phytochemicals of <i>Hedyotis scandens</i> root used for the treatment of indigestion and stomachache (HS)	164
Figure 4.3.1.j	Qualitative estimation of phytochemicals of <i>Fraxinus floribunda</i> bark used for the treatment of diabetes (FF)	164
Figure 4.3.1.k	Qualitative estimation of phytochemicals of herbal formulation used for the treatment of food poisoning (FP)	165
Figure 4.3.2.a	Total phenol content of studied eight herbal formulations	167
Figure 4.3.2.b	Total flavonoid content of studied eight herbal formulations	167
Figure 4.3.2.c	Total orthodihydric phenol content of studied eight herbal formulations	168
Figure 4.3.2.d	Total alkaloid content of studied eight herbal formulations	168
Figure 4.3.2.e	Total tannin content of studied eight herbal formulations	169
Figure 4.3.2.f	Total steroid content of studied eight herbal formulations	169
Figure 4.4.1	Antimicrobial activity of standard antibiotic streptomycin in various bacterial strains labeled as A, B, C, D and E	174
Figure 4.4.2	Antimicrobial activity of ethanolic extract of herbal formulation AR in various bacterial strains labeled as	175
Figure 4.4.3	Antimicrobial activity of aqueous extract of herbal formulation AR in various bacterial strains labeled as A, B, C, D and E	176

<i>Figure No.</i>	<i>Figure</i>	<i>Page No.</i>
Figure 4.4.4	Antimicrobial activity of ethanolic extract of herbal formulation BP in various bacterial strains labeled as A, B, C, D and E	177
Figure 4.4.5	Antimicrobial activity of aqueous extract of herbal formulation BP in various bacterial strains labeled as A, B, C, D and E	178
Figure 4.4.6	Antimicrobial activity of aqueous extract of herbal formulation AS in various bacterial strains labeled as A, B, C, D and E	179
Figure 4.4.7	Antimicrobial activity of ethanolic extract of herbal formulation AS in various bacterial strains labeled as A, B, C, D and E	180
Figure 4.4.8	Antimicrobial activity of aqueous extract of herbal formulation FP in various bacterial strains labeled as A, B, C, D and E	181
Figure 4.4.9	Antimicrobial activity of ethanolic extract of herbal formulation FP in various bacterial strains labeled as A, B, C, D and E	182
Figure 4.4.10	Antimicrobial activity of aqueous extract of herbal formulation GS in various bacterial strains labeled as A, B, C, D and E	183
Figure 4.4.11	Antimicrobial activity of ethanolic extract of herbal formulation GS in various bacterial strains labeled as A, B, C, D and E	184
Figure 4.4.12	Antimicrobial activity of aqueous extract of herbal formulation HP in various bacterial strains labeled as A, B, C, D and E	185
Figure 4.4.13	Antimicrobial activity of ethanolic extract of herbal formulation HP in various bacterial strains labeled as A, B, C, D and E.	186

Figure No.	Figure	Page No.
Figure 4.4.14	Antimicrobial activity of aqueous extract of herbal formulation TS in various bacterial strains labeled as A, B, C, D and E	187
Figure 4.4.15	Antimicrobial activity of ethanolic extract of herbal formulation TS in various bacterial strains labeled as A, B, C, D and E	188
Figure 4.4.16	Antimicrobial activity of aqueous extract of herbal formulation FF in various bacterial strains labeled as A, B, C, D and E	189
Figure 4.4.17	Antimicrobial activity of ethanolic extract of herbal formulation FF in various bacterial strains labeled as A, B, C, D and E	190
Figure 4.5.1	Anticancer activity of herbal formulation extracts against WRL-68 cell line	194
Figure 4.5.2	IC50 values of MTT assay of herbal formulation extracts against WRL-68 cell line	194
Figure 4.6.1	Alpha glucosidase inhibiting activity of herbal formulation HP for heart palpitation	195
Figure 4.6.2	Alpha glucosidase inhibiting activity of herbal formulation AR for arthritis	195
Figure 4.6.3	Alpha glucosidase inhibiting activity of herbal formulation BP for high blood pressure	196
Figure 4.6.4	Alpha glucosidase inhibiting activity of herbal formulation GS for gastritis.	196
Figure 4.6.5	Alpha glucosidase inhibiting activity of herbal formulation AS for asthma	197
Figure 4.6.6	Alpha glucosidase inhibiting activity of herbal formulation FP for food poisoning	197

Figure No.	Figure	Page No.
Figure 4.6.7	Alpha glucosidase inhibiting activity of herbal formulation TS for tonsilitis	198
Figure 4.6.8	Alpha glucosidase inhibiting activity of herbal formulation FF (bark of <i>Fraxinus floribunda</i>) for diabetes	198
Figure 4.7.1	DPPH' scavenging activity of herbal formulations (IC50 mg/ml)	201
Figure 4.7.2	ABTS' scavenging activity of herbal formulations (IC50 mg/ml)	201
Figure 4.7.3	Superoxide scavenging activity of herbal formulations (IC50 mg/ml)	202
Figure 4.7.4	Nitric oxide scavenging activity of herbal formulations (IC50 mg/ml)	202
Figure 4.7.5	Metal chelating activity of herbal formulations (IC50 mg/ml)	203
Figure 4.7.6	Ferric reducing antioxidant power of herbal formulations (mg AAE/gEW) [AAE: Ascorbic Acid Equivalent]	203
Figure 4.8	Angiotensin converting enzyme inhibiting activity of extracts of herbal formulations	208
Figure 4.9	Principal component analysis of phytochemical content, antioxidant activity and antidiabetic activity of the studied eight herbal formulations	211
Figure 4.10.1.a	DPPH radical scavenging activity of process variation extracts of BOFF	215
Figure 4.10.1.b	ABTS+ radical scavenging activity process variation extracts of BOFF	215
Figure 4.10.1.c	Superoxide scavenging activity process variation extracts of BOFF	215
Figure 4.10.1.d	Nitric oxide scavenging activity process variation extracts of BOFF	215
Figure 4.10.1.e	Metal chelating activity process variation extracts of BOFF	215

Figure No.	Figure	Page No.
Figure 4.10.1.f	Ferric reducing antioxidant power process variation extracts of BOFF	215
Figure 5.10.2.a	Total phenol content process variation extracts of BOFF	216
Figure 4.10.2.b	Total flavonoid content process variation extracts of BOFF	216
Figure 4.10.2.c	Total orthodihydric phenol content process variation extracts of BOFF	216
Figure 4.10.3	α -glucosidase inhibiting activity of aqueous extracts of <i>F. floribunda</i>	217
Figure 4.11.1.a	Percentage inhibition of paw oedema by BOFF extract compared with aspirin	219
Figure 4.11.1.b	Anti-inflammatory activity of <i>F. floribunda</i> by rat paw edema method	220
Figure 4.11.2.a	Effect of BOFF extracts on SGOT level in hepatotoxic rats	221
Figure 4.11.2.b	Effect of BOFF extracts on ALP level in hepatotoxic rats	221
Figure 4.11.2.c	Effect of BOFF extracts on SGPT level in hepatotoxic rats	222
Figure 4.11.2.d	Effect of BOFF extracts on Bilirubin level in hepatotoxic rats	222
Figure 4.11.3.f	Liver histopathology of Streptozotocin induced rats and effects of bark of <i>Fraxinus floribunda</i> (FF) on it	227
Figure 4.11.3.g	Images of <i>in vivo</i> antidiabetic study	228
Figure 4.12.1.a	Schemes of fraction for bioassay guided purification of <i>Fraxinus floribunda</i> bark	231
Figure 4.12.1.b	DPPH and ABTS radical scavenging activities of fractions obtained from successive extraction	232
Figure 4.12.1.c	Total phenol content of fractions obtained from successive extraction	232
Figure 4.12.1.d	Total flavonoid content of fractions obtained from successive extraction	232
Figure 4.12.e	DPPH scavenging activity and total flavonoid content of fractions of <i>F. floribunda</i> obtained from column chromatography	233

Figure No.	Figure	Page No.
Figure 4.12.1.f	TLC profiling of bioactive sub-fractions of <i>F. floribunda</i> bark obtained from column chromatograph	234-237
Figure 4.12.1.g	Alpha glucosidase inhibiting activity of merged fractions from TLC profiling	238
Figure 4.12.2.a	HR- GCMS scanning chromatogram of fraction FF-1 of <i>F. floribunda</i>	239
Figure 4.12.2.b	Structure and MS spectrum of Dec-5-ene-3,7-diyne-2,9-dimethyl compared with NIST Library Spectral Database	240
Figure 4.12.2.c	Structure and MS spectrum of 2(1H)-Quinolinone, hydrazone compared with NIST Library Spectral Database	240
Figure 4.12.2.d	Structure and MS spectrum of 3-cyclohexen-1-ol,4-methyl-1-(1-methylethyl) compared with NIST Library Spectral Database	241
Figure 4.12.2.e	Structure and MS spectrum of Flavone compared with NIST Library Spectral Database	241
Figure 4.12.2.f	Structure and MS spectrum of Coumarin,6-amino-3-phenyl compared with NIST Library Spectral Database	242
Figure 4.12.2.g	Structure and MS spectrum of Heptadecanoic acid compared with NIST Library Spectral Database	242
Figure 4.12.2.h	Structure and MS spectrum of Acacetin compared with NIST Library Spectral Database	243
Figure 5.12.2.i	Structure and MS spectrum of 10-Octadecenoic acid, methyl ester compared with NIST Library Spectral Database	243
Figure 4.12.2.j	Structure and MS spectrum of Palustric acid compared with NIST Library Spectral Database	244
Figure 4.12.2.k	Structure and MS spectrum of Elaidic acid isopropyl ester compared with NIST Library Spectral Database	244
Figure 4.12.3.a	TLC profiling of the merged fractions and the bands scratched out to obtain the extract	248
Figure 4.12.3.b	Alpha glucosidase inhibiting activity of each scratched bands from the TLC profiling of the merged fractions	248

Figure No.	Figure	Page No.
Figure 4.12.3.c	TLC profiling of Fraction-1 to obtain extract for NMR analysis (UV-365 nm)	249
Figure 4.12.3.d	TLC profiling of Fraction-1 to obtain extract for NMR analysis (visible light)	249
Figure 5.12.3.e	1-H NMR spectra of commercially available 2-hydrazinoquinoline purchased from Sigma dissolved in methanol	250
Figure 4.12.3.f	1-H NMR spectra of column and TLC purified extract (FIRST BAND) of <i>Fraxinus floribunda</i> bark dissolved in methanol	250
Figure 4.12.3.g	1-H NMR spectra of column and TLC purified extract (SECOND BAND) of <i>Fraxinus floribunda</i> bark dissolved in methanol	251
Figure 4.12.3.h	Possible NMR spectrum and the functional group with the structure of 2-hydrazinoquinoline and the prediction of the 1-H NMR	252
Figure 4.12.3.i	Possible NMR spectrum and the functional group with the structure of the first band of the extract of <i>Fraxinus floribunda</i> bark and the prediction of 1-H NMR	253
Figure 4.12.3.j	Possible NMR spectrum and the functional group with the structure of the second band of the extract of <i>Fraxinus floribunda</i> bark and the prediction of 1-H NMR	254
Figure 5	A flowchart of study of ethnomedicine from traditional system to the identification of bioactive compound responsible for its bioactivity.	294